PIPELINE
LEAD
PROGRAMS
AU409 — Liver Cancer & CRCLM
Status: Phase 1 Clinical Trial
AI-discovered, first-in-class oral transcription modulator demonstrating encouraging clinical activity in advanced hepatocellular carcinoma (HCC), including a durable complete response* by mRECIST. Development is also targeting colorectal cancer liver metastases (CRCLM).
*Partial response by RECIST 1.1.
AU018 — Heart-Safe Chemotherapy
Status: Preclinical / IND-Enabling Studies
AI-discovered therapeutic program developed and validated in collaboration with SCT, designed to improve the cardiac safety of anthracycline chemotherapy while preserving anticancer efficacy.
100+
Diseases